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did not have LI at 1 month post- AlloHSCT. On multivariate
analysis, only bloodstream bacterial infections (P ¼ .0059)
and invasive fungal infections (P ¼ .0020) were signiﬁcant
risk factors for developing LI at 1 month. On multivariate
analysis for risk factors for TRM, only LI at 1 month post-
AlloHSCT (P ¼ .0001), primary graft failure (P ¼ .0096) and
bloodstream bacterial infections (P ¼ .0328) were signiﬁcant.
However, LI prior to AlloHSCT conditioning was not associ-
ated with higher TRM.
Conclusions: TRM among pediatric patients with LI at 1
month post-AlloHSCT is extremely high, with infections
being the primary risk factor for LI.Table 1
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Extracorporeal photopheresis (ECP) is an established
second line treatment option for graft versus host disease
post hematopoietic progenitor cell transplant. At our center
the Therakos Cellex has replaced the UVAR-XTS machine for
ECP since 2009. We reviewed the records of 385 procedures
using the Therakos Cellex. Nine patients underwent ECP for
GVHD. The median age was 13.5 years (range 3.7 to 24) and
weight was 49.2 kg (range 18.5-86.3). ECP was initiated at
a median of 7.5 months (range 0.3-34.8) from the onset of
GVHD. The mean duration per procedure was 106 minutes
(range 60-205). Fifteen (3.9%) procedures were cancelled and
10 (2.6%) were delayed with central venous line (CVL) issues
being the most frequent problem. Instillation of prophylactic
tissue plasminogen activator (tPA) in the CVL lumens prior to
a procedure was instituted 6 months before the end of study
period, to reduce the incidence of CVL related occlusions and
sluggish returns. With change in practice, fewer CVL related
occlusions were observed (4.7% vs. 2.3%). There was one
episode of CVL-associated thrombosis and one episode of
delayed bleeding (mild and spontaneously resolved). There
were four episodes of viral reactivation, 4 CVL-associated
infections (1142 catheter days) and 1 episode of systemic
inﬂammatory response syndrome. No patient experienced
hypotension that requiredmedical intervention. Although no
additional adverse events were noted, there was consider-
able blood exposure in the smallest patients because of the
need for machine blood prime. The Therakos Cellex appears
to be safe and well-tolerated in 385 procedures performed in
our institution. This is the ﬁrst report regarding the safety
and tolerability of this device for ECP in children and young
adults.Disease MRD 0.01% Total (n) Relapse (n) Relapse
Rates
Acute
lymphoblastic
leukemia
No 20 7 35%
Yes 11 7 64%
Acute myelogenous
leukemia
No 15 3 20%
Yes 11 4 36%
Mixed phenotype
acute leukemia
No 8 3 38%
Yes 1 0 0%287
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Background: Relapse is the primary cause of treatment
failure post alloHCT. We sought to identify risk factors that
predict relapse of hematologic malignancies after allogeneic
hematopoietic cell transplantation (alloHCT) to identify
those at highest risk of relapse who may beneﬁt from novel
therapies.
Design: This was a single institution, retrospective cohort
study of children with acute lymphoblastic leukemia (ALL),
acute myelogenous leukemia (AML), mixed phenotypic acute
leukemia (MPAL) and myelodysplastic syndrome (MDS) who
had undergone alloHCT between 1/1/2003 and 12/31/2010.
Relapse was deﬁned as any evidence of increasing disease
post-alloHCT, including minimal residual disease (MRD).
Relapse-free survival (RFS) was estimated by the Kaplan-
Meier method and the log-rank test used to assess univariate
associations with various characteristics. A Cox proportional
hazards model was used to identify factors jointly associated
with RFS.
Results: Of 70 children who underwent a myeloablative HCT
for MDS or acute leukemia in complete remission at the time
of HCT, 24 (34%) relapsed at a median of 214 days (range 1
month- 57 months) post-HCT. Relapse rates by disease were
14/31 (45%) for ALL; 7/26 (27%) for AML; 3/9 (33%) for MPAL;
0/4 (0%) for MDS. Univariate analysis demonstrated that
black race, central nervous system (CNS) disease at diagnosis
(Figure 1), greater number of regimens given to induce
remission and MRD pre-HCT were associated with higher
relapse probability. In a Cox model, either two or more
regimens needed to achieve remission or the presence of
both pre-HCT MRD and CNS disease were approximately
equally predictive of increased relapse risk. In patients with
ALL, CNS disease was more highly associated with relapse
risk than MRD. For those who were MRD negative, based
on 19 total patients, the presence of CNS disease at
diagnosis (n¼2) was signiﬁcantly associated with higher
relapse risk (P < .0001).
Conclusion: We identiﬁed CNS involvement at diagnosis as
a novel risk factor associated with relapse risk after alloHCT.
This may be due to inherent biologic differences leading to
higher risk disease, or as a sanctuary site, the CNSmay be less
amenable to an allogeneic effect. These patients may beneﬁt
from earlier or more intensive CNS-directed therapy to
reduce relapse risk. Validation of these risk factors in a larger
population and development of a prognostic score to identify
those at highest risk of relapse in addition to a biology study
to evaluate for MRD in the CNS using ﬂow cytometery is
planned. The goal is for prospective use of this prognostic
tool in the development of relapse prevention trials.
